1. Modifications in Mutational Landscape in Patients with Lower Risk MDS without 5Q Deletion Receiving Azacitidine Are Correlated with Clinical Response. (April 2017) Authors: Sanchez-Garcia, J.; Hernandez-Sanchez, J.M.; Falantes, J.; Benito, R.; Medina, A.; Lumbreras, E.; Hernandez-Mohedo, F.; Hermosin, L.; Bailen, A.; Maria, S.; Casaño, J.; Calderon, C.; Labrador-Mateo, M.; Serrano, J.; Hernandez-Rivas, J.M. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗